Hemato Onco Flashcards

Question

Immunophenotype WM

Answer 1

CD19+, CD20+, sIgM+ CD5+/-

Answer 2

t(1:14) t(3:14)

Answer 3

CD16+, CD56+

Answer 4

Uniform amplification of 9p24.1 Expression of PDL-1 and PDL-2 Sourrounding cells express PD-1

Answer 5

Age> 45 M Stage IV Alb<4 Lympho< 500 WBC > 15K Hb< 10.5 ## Footnote 1 disease, 2 pt, 4 lab

Answer 6

30 with B Symp 50 without B symp

Answer 7

8 years post RT or Age 40

Answer 8

Age>60 Hb<12 LDH Stage III/IV >4 lymph nodes

Answer 9

0-1- 70% 2- 50% 3-5- 35%

Answer 10

Splenectomy

Answer 11

Age ECOG Stage III/IV 2 extranodal LDH

Answer 12

0 - 95% 1-2- 80% 3-5- 50%

Answer 13

CKD Hyponatremia Hypoalbuminemia Age> 60

Answer 14

Methylene blue

Answer 15

30% in 10 years

Answer 16

Alb 3.5 b2mg 3.5, 5.5 LDH FISH

Answer 17

I- 60 months II- 40 months III- 30 months

Answer 18

Non IgG FLC ratio M protein > 1.5 in LC MM k/l > 8

Answer 19

Hold And resume with lower dose

Answer 20

Nf-kappa B

Answer 21

FHx, Obesity Agent Orange, 9/11 survivors

Answer 22

FLC ratio has to be normal in sCR

Answer 23

t(4:14), t(14:16), t(14:20) 17p, gain 1q

Answer 24

1st line RX4 (including maintenance, but not approved) If very advanced BR 2nd line BTKi/splenectomy

Answer 25

Risk score for SMZL Hemoglobin PLT LDH Lymphadenopathy

Answer 26

SMILE Steroids, MTX, Ifosfamide, L-Asp, Etoposide

Answer 27

Luncatuximab Tafa-Len BR-Pola

Answer 28

PFS and OS benefit

Answer 29

ATE/VTE around 1-5% HTN

Answer 30

VRD +- ASCT PFS benefit in all subgroups

Answer 31

Primary refractory Relapse < 12 months Extranodal relapse AETHERA Phase III vs placebo Improved PFS

Answer 32

No monocytopenia in HCL-V

Answer 33

Repeat cladribine and add R BRAF i+R BRAF i+MECi Moxetumomab (anti CD22)

Answer 34

Dermatologic reactions Mucositis

Answer 35

aVWD Thrombocytopenia and thrombocytopathy Hyperviscosity FVIII def and possibly FX def if amyloidosis

Answer 36

Skin leisons Cytopenias, lymph, spleen, CNS

Answer 37

Tagraxofusp

Answer 38

NK1 antagonist (Emend)

Answer 39

3-4 months If no repsonse and no donor available- another course of ATG

Answer 40

Cafe au lait and skin pigmintation Solid tumors Short stature Absent radii

Answer 41

Older age Obesity, Low albumin, Low PLT

Answer 42

Erwinia-derived asparaginase

Answer 43

Hold and resume same dose

Answer 44

Avoid cryo unless bleeding May cause thrombosis

Answer 45

Effective also in blastoid, high Ki67 and p53

Answer 46

Life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders

Answer 47

VOD Pulmonary fibrosis Seizures

Answer 48

Until progression Dose escalation allowed Improves OS QUAZAR AML-001 Phase III vs placebo Improved OS, high MRD conversion rates

Answer 49

Poor prognosis MRD- is not predictive of good outcome

Answer 50

MRD- is not predictive of good outcome

Answer 51

Better respnose to 5-AZA-CHOP as 1st line

Answer 52

TP53 , CDKN2A, MYC, NOTCH1

Answer 53

Thiotepa is preferred RT is too toxic (TBC)

Answer 54

10%-20% pts post-IST

Answer 55

Monosomy 7- poor prognosis Trisomy 8- good response to IST

Answer 56

DNMT3A and ASXL1- poor BCOR, PIGA- good response to IST

Answer 57

MAC preferred in high risk pts with low HCT-CI or MRD+ If MRD(-) - MAC=RIC MAC - more GVHD RIC- more relpase

Answer 58

TBI with OS advantage More severe aGVHD

Answer 59

CML CLL Indolent LY MCL

Answer 60

Flu/Cy/ATG/Low TBI With PTCy and R post trasplant

Answer 61

Age, PLT, PB blasts, spleen

Answer 62

≥10% SF3B1

Answer 63

Neonates with IUT T cell depletion HL Fludarabine, Cladribine Alemtuzumab/ATG in context of hematologic melignancy or AA Transfusion from relatives All granulocyte transfusions

Answer 64

CD4, CD10, BCL6, PD1

Answer 65

Leukopharesis in WBC> 100 K IFN TKIs may be safe in late pregnancy

Answer 66

Less ATE, bleeding, progression to PMF in HU More VTE in HU

Answer 67

IgG-L IgA-L

Answer 68

WM MZL CLL DLBCL IgM MGUS

Answer 69

PLT > 200K - 20 mg bid PLT > 100K - 15 mg bid PLT >50K - 5 mg bid

Answer 70

For anemia Combined with prednisone ~60% ORR

Answer 71

FIP1L1-PDGFRA, PDGFRB, FGFR1, JAK2, BCR-ABL1 FACS for T cell KIT if mast cells in BMB Infectious WU ANCA if susp.

Answer 72

Administer chemo in 2nd 3rd trimester If possible postpone chemo in 1st trimester, consider termination of pregnancy

Answer 73

BRAF V600E 90% CD19, CD20, CD22 CD11c, CD25, CD103, CD123 No translocations

Answer 74

CAR-T (Tisa cell is not approved) R-ICE followed by ASCT PD1 i Bv

Answer 75

25% Anti epileptic, resprim, synto, PTU

Answer 76

HLA-DR15 predicts better response to immunosupressive Tx

Answer 77

Parvo FACS PEP IEP TCR ANA Anti-EPO Anemiogram Chest CT

Answer 78

COMFORT Phase III vs placebo or BAT End points- TSS50 and SVR35 Long FU showed OS advatage

Answer 79

No monoclone Normal IgM level Resolution of enlarged lymph nodes and enlarged spleen if present at baseline, Normal BMB

Answer 80

Reticulocytosis

Answer 81

Increased thrombosis, fibrosis, AML

Answer 82

Higher Hb and WBC

Answer 83

JAKi IMIDs HU IFN

Answer 84

~20% not clear if effects prognosis

Answer 85

Highest in same sex siblings if pt was diagnosed in young age HLA class II, HLA-A01 Non-hispanic whites

Answer 86

Fever, malaise, leukopenia, gastrointestinal symptoms, pneumonitis, and hepatitis

Answer 87

Continue as planned

Answer 88

More aGVHD and severe cGVHD Less graft failure with MAC

Answer 89

MDS AML CMML PMF CLL- agressive disease

Answer 90

80% Most commonly del13q

Answer 91

Retrospective studies PFS and OS

Answer 92

Autoimmune cytopenia

Answer 93

Zoledronic acid more effective with OS advantage (non randomized comparassion) Pamidronate better in CKD and has a lower rate of osteonecrosis of the jaw

Answer 94

Worse than idiopathic But overcome with ASCT

Answer 95

Skeltal DI Lung

Answer 96

NLP HL CD45+, CD20+, CD22+, CD79a+ Usually diagnosed at early stage with perpipheral lymphadenopathy

Answer 97

2 year May prolong if needed May shorten to 1 year if in CR after ASCT

Answer 98

Binds to RARa Disrupts the interaction of N-CoR and SMRT

Answer 99

Phase I- helathy volunteers- safety, tolerability, pharmacokinetics, and pharmacodynamics Phase II- patients- larger study- efficacy and dosing

Answer 100

Usually ASx 1:2M

Answer 101

Inhibition of DNA polymerase

Answer 102

* Gemcitabine * Oxaliplatin * Fluorouracil (5-FU) * Vincristine * Hydroxyurea * Vyxeos * Pegaspargase

Answer 103

t(4;11) MLL

Answer 104

High Decreased binding to megakaryo. But increased sensitivity

Answer 105

RNA reductase inhibitor

Answer 106

Palpitations

Answer 107

ATO with auto transplant consolidation

Answer 108

PML:RARA NPM1 CBF FLT3

Answer 109

ASXL1 SRSF2 U2AF1

Answer 110

KMT2D, MYD88, CD79B, PIM1, PD1 in Richter's

Answer 111

ASXL1, TET2, SETBP1, SRSF2

Answer 112

FISH- 200 Karyo- 20

Answer 113

Alterations that cannot be seen in a karyotype

Answer 114

Monosomal karyotype But can also be normal

Answer 115

Improves OS in T-LBL

Answer 116

Improves PFS

Answer 117

Young age Lung tranplant EBV negative pt receiving EBV positive organ

Answer 118

Discontinue

Answer 119

Drugs- Allopurinol, PPis, NSAIDS, ACEi Urine output less than 100-200 mL/hour Obesity CKD

Answer 120

10% May reduce effetiveness of Tx Monitor asparginase activity in mild cases of transfusion reactions

Answer 121

Older ager Obesity Leukopenia at diagnosis Mediastinal mass at diagnosis

Answer 122

AC and discontinue permamntatly

Answer 123

Ignore More common in young and obese pts, more common during consolidation

Answer 124

Continue Tx

Answer 125

Progression or failure to improve At least 3 days

Answer 126

Imatinib and bosutinib

Answer 127

Bortezomib Carfilzomib Thalidomide Pomalidomide Daratumumab DVTd KPd

Answer 128

In advanced stage cardiac disease Dexa 10 Velcade- give slowly and under supervision - may worsen HF

Answer 129

Check MRD If positive- consider prolonging or escalating Tx

Answer 130

BNP > 1800, 8500 Troponin > 40 delta FLC > 18

Answer 131

Tdt positive in B ALL sIg positive in BL

Answer 132

CMV reactivation

Answer 133

Allowed Different regimens

Answer 134

Ponatinib vs imatinib Phase III With low dose chemo backbone

Answer 135

> 10% at 6 months > 1% any time

Answer 136

Musculoskeletal pain

Answer 137

Rash AI cytopenia

Answer 138

Lysozyme-induced tubular damage

Answer 139

> 90% decrease in monoclone + Urine BJ < 100 mg/d + Negative PEP (IEP can be positive)

Answer 140

Immunoparesis >95% abberant cells

Answer 141

Primary refractory Relapse < 12 months Second relapse (or after ASCT)

Answer 142

PLL- CD5- and CD22+

Answer 143

1st trimester - steroids+vinblastine 2nd- 3rd trimester- ABVD

Answer 144

AQUILA Dara improved OS For very high risk pts (not MAYO)

Answer 145

Cytopenias SIRS N/V Rash

Answer 146

Phenytoin Tegretol

Answer 147

SGLT2i Androgens

Answer 148

Exon 12 isolated polycythemia

Answer 149

RESPONSE Phase III vs BAT HU resistant pts End point of SVR35 and Hb decrease

Answer 150

Low-PV study Phase II Reduces need for phlebotomy

Answer 151

Cytopenia Infections Weight gain VZV Dyslipidemia/HTN

Answer 152

Reduces ferritin Improves the composite outcome of organ iron deposition and mortality

Answer 153

TI in all low risk Reduces ferritin

Answer 154

Echo Phase III vs BR Not published yet

Answer 155

ENRICH vs BR/R-CHOP PFS vs R-CHOP Chemo better in blastoid

Answer 156

Phase II all pts after chemo-immuno and BTKi High risk pts were included

Answer 157

Weight loss ≥10% in 6 months. Fevers 38.0°C for 2 weeks Night sweats for ≥1 month.

Answer 158

Increases risk for AIHA especially following FCR

Answer 159

>55% prolymphocytes in PB

Answer 160

Trisomy 12

Answer 161

CT to see if bulky disease and risk of TLS

Answer 162

Longer MRD- CR

Answer 163

GCSF Better not to decrease dose

Answer 164

PFS and OS

Answer 165

Increased mortality!!

Answer 166

An option Most of the data is after immun-chemo PFS advatage 1-1.5 years

Answer 167

Anti-psychotics Anti-convulsive Herbal

Answer 168

Leukplakia in the mouth Gray hair Nail changes Lung/Pulmonary fibrosis

Answer 169

HL Chemo Viral infections TB HIV

Answer 170

2 months of V 4 months of R

Answer 171

HUS Capillary leak syndrome

Answer 172

QT Rash LFT

Answer 173

MAC showed OS advantage Study stopped early

Answer 174

Cytopenias Contraindicated in PLT < 50K

Answer 175

Unmutated IGHV Positive Coombs

Answer 176

ALL- small/medium sized cells, scant cytoplasm, no granulation or auer rods

Answer 177

ALL- TdT, BCL2 BL- surface Ig, MYC

Answer 178

Cytoplasmatic

Answer 179

T-ALL Can be target for dara Tx

Answer 180

>5 cytogenetic abnormalites

Answer 181

Flow + NGS Better prognosis if both negative

Answer 182

AML- 100K ALL- 200K

Answer 183

Good prognosis in B-ALL

Answer 184

Blasts < 1000 on day 8 MRD at end of induction

Answer 185

Combination with voriconazole Can cause also axonal neuropathy

Answer 186

TOWER- in MRD relpase Phase III vs SOC BLAST- for residual MRD after induction Phase II

Answer 187

EMD Agressive disease

Answer 188

INO-VATE ALL Phase III vs SOC Improved CR, PFS and OS

Answer 189

MLL BCR:ABL1 NOTCH1 FLT3

Answer 190

> 25% = ALL < 25% = LBL

Answer 191

Down syndrome PMF

Answer 192

PRES Diffrentiation syndrome QT prolongation

Answer 193

To attain a MRD marker

Answer 194

Low Hb Instability Complications of central line

Answer 195

FISH panel OGM RNA sequencing

Answer 196

Thrombosis Excerbation of extramefullary hematopoeisis

Hemato Onco Flashcards

(255 cards)